Mall of America

Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFa agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease

Retrieved on: 
Tuesday, August 23, 2022
National, Inflammation, CEO, Tumor necrosis factor, Safety, Pain, Duane syndrome, Disease, Tissue, NIH, Clinical Ophthalmology (journal), DED, Hospital, Population, Fragment crystallizable region, Uveitis, Mall of America, MOA, Macular edema, POC, Quinze-Vingts National Ophthalmology Hospital, Patient, Pharmaceutical industry, Telescopic sight, Ophthalmology, Pecten oculi

Dry Eye is a multifactorial disease in which inflammation rapidly takes on a central role in sustaining the pathological state(1).

Key Points: 
  • Dry Eye is a multifactorial disease in which inflammation rapidly takes on a central role in sustaining the pathological state(1).
  • Licaminlimab (OCS-02) is currently being investigated by Oculis in Phase 2 clinical trials for the treatment of dry eye disease and uveitis.
  • I certainly look forward to the continued development and approval of OCS-02 in severe dry eye disease as these patients currently have limited treatment options."
  • EuDESEuropean Dry Eye Society https://www.dryeye-society.com/resources/dry-eye-disease-complex-interac...
    (2) Eric B Papas "The global prevalence of dry eye disease: A Bayesian view" 2021
    (5) Mukamal, R. Why is Dry Eye So Difficult to Treat?

Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease

Retrieved on: 
Tuesday, August 23, 2022
National, Inflammation, CEO, Safety, Pain, Duane syndrome, Disease, Tissue, NIH, Clinical Ophthalmology (journal), DED, Hospital, Population, Fragment crystallizable region, Uveitis, Mall of America, MOA, Macular edema, POC, Quinze-Vingts National Ophthalmology Hospital, Patient, Pharmaceutical industry, Telescopic sight, Ophthalmology, Pecten oculi

Dry Eye is a multifactorial disease in which inflammation rapidly takes on a central role in sustaining the pathological state1.

Key Points: 
  • Dry Eye is a multifactorial disease in which inflammation rapidly takes on a central role in sustaining the pathological state1.
  • In the US alone, there is currently between 16 million and 49 million people who have dry eye disease3.
  • Licaminlimab (OCS-02) is currently being investigated by Oculis in Phase 2 clinical trials for the treatment of dry eye disease and uveitis.
  • I certainly look forward to the continued development and approval of OCS-02 in severe dry eye disease as these patients currently have limited treatment options.

Wisdom Gaming Launches New Development Division, Wisdom Labs, to Expand Web3 Offerings

Retrieved on: 
Wednesday, August 17, 2022
Mall, Rocket League, Multimedia, PvP, Non-fungible token, Industry, Name, Blockchain, UX, Growth, Virtual reality, Marketing, Torrent, Gold rush, Decentralized finance, View, Partnership, Mall of America, DAPP, Gold, The Game Creators, Web 2.0, Kingdom Story Company, Entrepreneurship, Organization, Video game, Cryptocurrency, Web3, Wisdom

BLOOMINGTON, Minn., Aug. 17, 2022 /PRNewswire/ -- Wisdom Gaming, the emerging leader in esports entertainment, today announced Wisdom Labs, a new division that will expand the company's creative and development capabilities. Wisdom Labs enhances the company's internal broadcast and product offerings and provides services within the Web3 space for brand partners. With a focus on accountability and transparency, the team will be building out capabilities to focus on augmented reality, virtual reality, mobile game development, and Web3 integrations.

Key Points: 
  • Wisdom Labs enhances the company's internal broadcast and product offerings and provides services within the Web3 space for brand partners.
  • Wisdom Labs is the latest milestone for next gen esports and gaming media company Wisdom Gaming.
  • Service offerings include Web3 integrations, smart contract development, security audits, token development, NFTs, blockchain-based mobile game development, DAPP development and in-app purchase support.
  • In addition to Web3 services, Wisdom Labs offers Web2 capabilities including full-stack development, UX/UI design, Twitch extensions and ecommerce platform development.

MALL OF AMERICA CELEBRATES 30 YEARS OF RETAIL, ENTERTAINMENT, INNOVATION

Retrieved on: 
Thursday, August 4, 2022
Universe, Mall, Today (American TV program), Sea Life Minnesota Aquarium, Experience, Mall of America, National Center on Education and the Economy, Institute of technology, PI, NSYNC, IOS, NCAT, Escape, Robotics, Sri Lanka Institute of Advanced Technological Education, National Science Foundation, NSF, Rotunda, Knowledge, Restaurant, Minnesota State University, Mankato, Instagram, ATE, Twitter, Education, App Store (iOS/iPadOS), Nickelodeon Universe, Northland Community & Technical College, Parent, Pepsi, Google, Android, App store, Crayola, University, The Beach Boys, Minneapolis–Saint Paul International Airport, SEA, Organization, Amusement park, Science, STEAM, Facebook, Engineering, Technology, Northland College, Mathematics

BLOOMINGTON, Minn., Aug. 4, 2022 /PRNewswire/ -- Mall of America, the largest retail and entertainment complex in the United States, is celebrating 30 years on Aug. 11. Since 1992, Mall of America has pioneered an incredible retail, dining, and entertainment experience, becoming one of the nation's most visited attractions with more than 1.3 billion guests from every state across the United States and every continent in the world.

Key Points: 
  • BLOOMINGTON, Minn., Aug. 4, 2022 /PRNewswire/ -- Mall of America, the largest retail and entertainment complex in the United States, is celebrating 30 years on Aug. 11.
  • "Since Day One, Mall of America has exceeded expectations, and we're excited to continue doing just that for years to come."
  • Mall of America continues to be an innovator in delivering incredible retail, dining and entertainment since its doors first opened three decades ago.
  • Download the Mall of America app from the App Store for iOS or Google Play for Android.

Museum of Illusions® to Open New Museum in America's Biggest Mall

Retrieved on: 
Wednesday, August 3, 2022
Universe, People, Travel, Mall of America, The Lego Group, MOA, Museum, Multimedia, SEA, Creativity, City, B&B Theatres, CEO, Sea, Nickelodeon Universe, View, Tourism, Illusion, Mall

ATLANTA, Aug. 3, 2022 /PRNewswire/ -- Museum of Illusions®, a global leader in "edutainment" and the biggest chain of private museums worldwide, announced today the global brand's plan to open a new location in one of the most-visited malls in the United States. The brand new Museum of Illusions is set to open in Mall of America ("MOA") in Minneapolis, Minnesota in early 2023.

Key Points: 
  • The brand new Museum of Illusions is set to open in Mall of America ("MOA") in Minneapolis, Minnesota in early 2023.
  • Visitors to the new museum can expect a truly unforgettable experience, as the Minneapolis Museum of Illusions will be joining many entertainment attractions in this mall, home to more than 520 stores.
  • "Museum of Illusions is excited to bring its unique, interactive and immersive experience to one of the largest entertainment spaces in the world," said Jonathan Benjamin, CEO of Museum of Illusions.
  • For more information about the Museum of Illusions and its franchise opportunities, visit www.museumofillusions.com or email at [email protected] .

PACSUN LAUNCHES ALL NEW DENIM IN 2022 BACK-TO-SCHOOL CAMPAIGN

Retrieved on: 
Thursday, July 14, 2022
Metaverse, Culture, IRL, Leg, Social media, Multimedia, Mall of America, Virtual, Digital, View, Love, Facebook, Olson, Bear, NFT, Generation Z, Gen, Mall, Internet, Twitter, CA, TikTok, Personality, Public relations, PacSun, Instagram, Roblox, Discord

LOS ANGELES, July 14, 2022 /PRNewswire/ -- Today, Pacsun released its 2022 Back-to-School #MyDenimStory Campaign, launching an entirely new denim offering with an elevated new logo and premium branding package. Featuring over 200 fresh styles, Pacsun brings some of the emerging aesthetics to the mainstream, inclusive of genderless designs, 90's nostalgia and workwear inspired silhouettes.

Key Points: 
  • LOS ANGELES, July 14, 2022 /PRNewswire/ -- Today, Pacsun released its 2022 Back-to-School #MyDenimStory Campaign, launching an entirely new denim offering with an elevated new logo and premium branding package.
  • With that, the trend cycle that Pacsun has seen emerge is "anything goes" denim, and the retailer is voicing this to their audiences throughout the #MyDenimStory campaign, encouraging their community to engage in telling their personal denim stories.
  • All creators were involved in styling the campaign and their individual denim looks as part of the #MyDenimStory community.
  • Each Pacsun retail location will have denim themed decor throughout and window displays showcasing campaign talent and imagery.

Nilogen Oncosystems Announces Partnership with Scailyte AG to Provide Clinically Relevant Translational Platform Supporting Development of Immuno-Oncology Therapeutics in Oncology Clinical Trials and Ultimately to Support Personalized Medicine for Patient

Retrieved on: 
Tuesday, July 12, 2022
ETH Zurich, Precision medicine, LLC, Multimedia, Solution, Drug combination, Tumor microenvironment, Company, Exploration, Risk, Patient, CLIA, Drug discovery, Business, MD, Sutro Biopharma, Diagnosis, IVD, Proteomics, Cdx, Cancer, Drug development, Doctor of Philosophy, Partnership, Biomarker, Mall of America, Medical imaging

"Nilogen Oncosystems' capability to generate omics and multi-modal data from each therapeutic option and for each patient is unique.

Key Points: 
  • "Nilogen Oncosystems' capability to generate omics and multi-modal data from each therapeutic option and for each patient is unique.
  • Founded in 2013, Nilogen Oncosystems, LLC is an Oncology drug development company with CLIA certified facilities in Tampa, FL.
  • Our goal is to enable the development of more effective drug and drug combinations, and reduce the cost and risk associated with clinical trials.
  • Nilogen's commitment to testing and customizing cancer drug development is proven and yields unparalleled results for its clients.

2022 Insights on Liver Fibrosis Drugs in Development - by Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 12, 2022
General Health, Pharmaceutical, Health, Molecule, Route of administration, Target, SEC, Research, News, History, Mall of America, Key, R, Cirrhosis, Administration, Therapy, Decision-making, Dietary supplement, Medical device

The "Liver Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Liver Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Liver Fibrosis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases.
  • Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

2022 Renal Failure Drugs in Development Report - by Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 7, 2022
Health, Pharmaceutical, Molecule, SEC, R, Mall of America, Decision-making, Therapy, Key, Administration, Kidney failure, History, News, Research, Target, Route of administration, Pharmaceutical industry, Medical device

The "Renal Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Renal Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive information on the therapeutics under development for Renal Failure, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases.
  • Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

2022 Insights on the Baculoviral IAP Repeat Containing Protein 5 Drugs in Development - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 29, 2022
Health, Pharmaceutical, Molecule, Mall of America, Decision-making, Administration, Research and development, Product description, Research, BIRC5, Apoptosis, R, Key, History, Survivin, Therapy, SEC, News, Route of administration, Pharmaceutical industry

The "Baculoviral IAP Repeat Containing Protein 5 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Baculoviral IAP Repeat Containing Protein 5 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • This report provides in depth analysis on Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted pipeline therapeutics.
  • The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.